[Pregnancy and HIV].
The issues raised have evolved over the last few years. The rate of mother-to-child transmission has decreased, mostly as a consequence of antiretroviral therapies. However, these drugs can have toxicity such as mitochondrial diseases in the infant, whose incidence and long term consequences are still unknown. The choice of therapy should be based on an estimate of benefit on risk on a case-to-case basis. If the patient requires an effective antiretroviral combination, it should not be withheld because of the pregnancy. If the mother does not require therapy for her own health, prevention of vertical transmission is based on zidovudine monotherapy beginning in the third trimester, which is most effective when combined with elective caesarean delivery. Interdisciplinary care must include clear information in a climate of dialogue with the mother.
Mandelbrot
L
L
Service de gynécologie-obstétrique, Hôpital Cochin-Port-Royal, Paris.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D002585:Cesarean Section; D018890:Chemoprevention; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission*; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D017240:Mitochondrial Myopathies / Q000139:chemically induced; D010353:Patient Education as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology*; D011263:Pregnancy Trimester, Third; D018570:Risk Assessment; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015215:Zidovudine
Grossesse et VIH.